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SObjective: The prognostic relevance of subtypes within type B thymomas is controversial. The objective of this
study was to evaluate the utility of World Health Organization (WHO) classification in patients with type B
thymoma.
Methods: This was a retrospective review of 100 patients who underwent thymectomy for WHO type B
thymoma. Recurrence patterns and survival were compared among subtypes.
Results: There were 22 type B1 tumors, 43 type B2 tumors, and 35 type B3 tumors. Incomplete resection
occurred in 5 patients with type B1 thymoma, 8 with type B2 thymoma, and 8 with type B3 thymoma
(P ¼ .87). Of the 79 patients with complete resection, tumor recurrence occurred in 1 (5.9%) patient with
type B1 thymoma, 2 (5.7%) with type B2 thymoma, and 2 (7.4%) with type B3 thymoma, and all of these patients
had Masaoka stage III disease. Disease-free survival at 5 years was 93%, 85%, and 82% in type B1, B2, and B3,
respectively (B1 vs B2; P¼ .79; B2 vs B3; P¼ 0.6). Disease-free survival at 5 years was 94%, 100%, 61%, and
50% in Masaoka stages I, II, III, and IV, respectively (I vs II; P ¼ .26; II vs III; P ¼ .028; III vs IV; P ¼ .002).
Conclusions: Tumor recurrence was significantly associated with advanced Masaoka stage regardless of the
WHO subtype of type B thymomas. Given the heterogeneity of WHO type B thymomas, Masaoka stage should
always be considered when predicting prognosis and planning adjuvant treatment for patients with type B
thymomas. (J Thorac Cardiovasc Surg 2010;139:1431-5)Supplemental material is available online.
The World Health Organization (WHO) histologic types of
thymomas are based on morphologic features1 and closely
correlate with the Masaoka staging system, reflecting the
extent and invasiveness of thymomas.2-7 However, when
‘‘biologically aggressive’’ type B2 or B3 thymomas are
completely resected at an ‘‘early’’ Masaoka stage, it is diffi-
cult to determine the need for adjuvant treatment in such pa-
tients. It is still unclear whether predicting prognosis or
planning adjuvant treatment can be based only on the
WHO classification regardless of the Masaoka staging sys-
tem. In particular, the prognostic relevance of subtypes
within type B thymomas remains controversial, inasmuch
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type B histology.
We hypothesized that the Masaoka staging system would
reflect the disease status of patients with thymoma and thus
predict the prognosis better than the WHO classification.
The objectives of this study were (1) to compare the recur-
rence patterns and long-term survival of type B thymoma
subtypes based on the Masaoka staging system as well as
the WHO classification and (2) to evaluate the utility of
the WHO classification in patients with type B thymomas.PATIENTS AND METHODS
Patients
Between December 1994 and February 2008, 265 consecutive patients
underwent thymectomy for thymic epithelial tumors at our institution. Of
these, 100 patients had WHO type B thymomas and were included in the
study population. Their medical records were retrospectively reviewed to
compare the clinical characteristics, recurrence pattern, and long-term sur-
vival among B1, B2, and B3 thymoma subtypes. The study was reviewed
and approved by the Institutional Review Board of Samsung Medical
Center.
All patients had extended thymectomy, which was defined as the resec-
tion of the entire thymus and mediastinal fat tissue between both phrenic
nerves. A median sternotomy was done in all patients except in cases in
which a posterolateral thoracotomy was also needed so that an en bloc ex-
trapleural pneumonectomy could be performed for unilateral pleural dis-
semination. Resection was defined as incomplete when microscopic (R1)
or macroscopic (R2) residual tumor was present at the end of the surgical
procedure. Mostly, patients with WHO type B2 or B3 thymomas or at
advanced Masaoka stage III or IVa disease received adjuvant treatment, in-
cluding radiation therapy, chemotherapy, or concurrent chemoradiation.diovascular Surgery c Volume 139, Number 6 1431
Abbreviations and Acronyms
DFS ¼ disease-free survival
OS ¼ overall survival
WHO ¼ World Health Organization
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With the use of hematoxylin–eosin stained sections derived from paraf-
fin-embedded blocks, histologic diagnosiswas re-evaluated on all specimens
by a pathologist who was blinded to clinical information. Type B thymomas
were subclassified according to the WHO classification as follows: type B1
thymomas are predominantly cortical, B2 thymomas are cortical, and B3
thymomas are well-differentiated thymic carcinomas.When thymomas con-
tained more than one subtype (eg, combined B1þB2 thymomas), they were
categorized into the predominant subtype to facilitate analysis. Tumor stage
was determined following the scheme suggested by Masaoka and associ-
ates.8 Stage I disease indicates macroscopically completely encapsulated
thymomaswith nomicroscopically determined capsular invasion; stage II in-
dicates macroscopic invasion into the surrounding fatty tissue or mediastinal
pleura, or microscopic invasion into the capsule; stage III indicates macro-
scopic invasion into neighboring organs (ie, pericardium, great vessels,
lung); stage IVa indicates pleural or pericardial dissemination; and stage
IVb indicates lymphogenous or hematogenous metastasis.
Follow-up and Statistical Analysis
Patients were regularly evaluated by computed tomography scans every
3 months for the first 2 years after the operation and then every 6 months
thereafter. Student t tests and the c2 tests or Fisher’s exact tests were used
to compare the continuous and categorical variables, respectively. All
deaths were considered as events, regardless of whether or not they were
thymoma-related. Overall survival (OS) was defined as time from the date
of thymectomy to death from any cause. Disease-free survival (DFS) was
defined as time from the date of thymectomy to recurrence or death. OS
and DFSwere calculated by the Kaplan–Meier method. OS and DFS among
subtypes were compared by the log–rank test. To determine which factors
were significantly associated with survival, we performed a multivariate
analysis using the Cox proportional hazards model.RESULTS
Clinical and Histopathologic Findings
There were 52 men and 48 women, with a mean age of
50.8  12.9 years, ranging from 23 to 79 years. Twenty-
two (22%) patients had type B1 thymomas, 43 (43%) had
type B2 thymomas, and 35 (35%) had type B3 thymomas.
Thirteen (13%) patients had myasthenia gravis. The site of
extrathymic invasion was lung in 15 patients, pericardium
in 8, superior vena cava in 3, and innominate vein in 3.
The correlation between WHO subtype and Masaoka stage
is summarized in Table 1. Although type B1 thymomas
tended to correlate with early Masaoka stages, as compared
with type B2 or B3 thymomas, the correlation was not statis-
tically significant (P ¼ .7).Treatment Modalities and Complete Resection
The treatment modalities performed in our series are sum-
marized in Table E1 according to WHO histologic type.1432 The Journal of Thoracic and Cardiovascular SurTwo (7%) patients received neoadjuvant chemotherapy fol-
lowed by extrapleural pneumonectomy owing to the possi-
bility of stage IVa disease. Extrapleural pneumonectomy
(n ¼ 3) and pneumonectomy with partial pleurectomy
(n ¼ 2) was performed in 5 patients, and complete resection
was achieved in 2 of those patients. Postoperative adjuvant
therapy was given to 74 (74%) patients. Sixty-seven
(67%) patients received adjuvant radiotherapy. There was
no significant difference in the frequency of adjuvant treat-
ment among the 3 subtypes (P¼ .3). Complete tumor resec-
tion (R0) in types B1, B2, and B3 thymomas was achieved in
77%, 81%, and 77%, respectively. In 14 patients with stage
IVa disease, multiple disseminated pleural nodules were un-
expectedly detected at surgery, whereas there was focal mi-
croscopic involvement of the resection margin in 7 patients
with stage III disease. Although the incidence of incomplete
resection was not different among the 3 subtypes (P ¼ .87),
all the tumors that were incompletely resected were either
Masaoka stage III or IVa (Table 2).
Recurrence and Survival
No in-hospital mortality was noted during the postopera-
tive period. Themedian follow-up timewas 49months, rang-
ing from 5 to 159 months. No significant difference was
found in the follow-up duration among the 3 subtypes (P ¼
.73). During follow-up, 6 patients died. The cause of death
included radiation pneumonitis in 2 patients, cardiac toxicity
owing to doxorubicin (Adriamycin) in 1, aplastic anemia in
1, pneumonia resulting from myasthenic crisis in 1, and thy-
moma-related death in 1. OS was 96% at 5 years and 87% at
10 years for the entire group. There was no significant differ-
ence in OS among the 3 WHO subtypes (B1 vs B2, P¼ .49;
B2 vs B3, P¼ .17; Figure 1, A). There was no significant dif-
ference inOS among the 4Masaoka stages (I vs II,P¼ .26; II
vs III, P ¼ .61; III vs IVa, P ¼ .3; Figure 1, B).
Among the 79 patients who had complete resection, tu-
mor recurrence occurred in 1 (5.9%) with type B1 thymoma,
2 (5.7%) with type B2 thymoma, and 2 (7.4%) with type B3
thymoma. All of these had Masaoka stage III disease (Table
3). Of the 5 patients with recurrent disease, 4 patients had
pleural dissemination and 1 had pulmonary metastasis. All
but 1 of these patients had undergone adjuvant radiation
therapy (Table E2). Of the 21 patients who had incomplete
resection, 3 (14.3%) patients have died of thymoma during
follow-up, whereas 18 (85.7%) were still alive even with
progressive disease at the last follow-up point.
DFS at 5 years was 93% for patients with type B1 thymo-
mas, 85% for type B2 thymomas, and 82% for type B3 thy-
momas (Figure 2, A). DFS at 5 years was 94%, 100%,
61%, and 50% in patients with Masaoka stage I, II, III, and
IVdisease, respectively (Figure 2,B).Nodifferencewas found
inDFS among the 3WHO subtypes (B1 vsB2,P¼ .79; B2 vs
B3, P ¼ .6). However, when based on the Masaoka staging
system, there was a significant difference in DFS betweengery c June 2010
TABLE 1. Distribution of Masaoka stage according toWHO subtypes
for all patients
WHO subtype
B1 (n ¼ 22) B2 (n ¼ 43) B3 (n ¼ 35)
Stage No. % No. % No. %
I 10 45 19 44 9 25
II 5 23 9 21 10 29
III 4 18 8 19 10 29
IVa 3 14 7 16 6 17
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stage III and stage IVa disease (I vs II, P ¼ .26; II vs III, P
¼ .028; III vs IVa, P¼ .002; Figure 2, B). No significant fac-
tors were found to be associated with overall survival in both
univariate and multivariate analyses. With regard to DFS,
Masaoka stage (hazard ratio, 3.11; 95% confidence interval,
1.5–6.46; P ¼ .002) and tumor size (hazard ratio, 1.47; 95%
confidence interval, 1.16–1.87; P ¼ .002) were identified as
independent factors that affected survival in multivariate
analysis.FIGURE 1. A, Comparison of overall survival of all patients amongWHO
subtypes. B, Comparison of overall survival of all patients among Masaoka
stages.DISCUSSION
The current WHO classification of thymic epithelial tu-
mors is based on the morphology of the epithelial cells as
well as the lymphocyte/epithelial cell ratio.1 Since the intro-
duction of the WHO classification system in 1999,1 several
authors have evaluated the prognostic relevance of this his-
tologic classification in patients with thymomas. Okumura
and colleagues2 reviewed 273 patients with thymic tumors
and showed that the WHO histologic types reflect the onco-
logic behavior of thymoma and that the WHO classification
may be helpful in clinical practice for the assessment and
treatment of patients with thymoma. Additionally, Naka-
gawa and associates3 demonstrated that the WHO histologic
classification significantly correlates with clinical stage and
can thus predict the prognosis of patients with thymoma.
There is widespread agreement that the prognosis of type
A and AB thymomas is superior to that of type B and C thy-
momas.2-7 This is related to the observation that the propor-
tion of thymoma at an advanced stage gradually increases
from type A to C. However, the prognostic relevance among
type B thymoma subtypes is still controversial. Some have
shown that patients with type B3 thymomas have worseTABLE 2. Frequency of incomplete resection according to WHO
subtypes and Masaoka stages for all patients
WHO subtype
B1 B2 B3
Overall (%) 5/22 (23) 8/43 (19) 8/35 (23)
Stage I 0/10 0/19 0/9
Stage II 0/5 0/9 0/10
Stage III 2/4 3/8 2/10
Stage IVa 3/3 5/7 6/6
The Journal of Thoracic and Carprognosis than those with type B2 thymomas,2,3 whereas
others have reported no significant difference in survival be-
tween these 2 groups.4,5,9,10 This discrepancy in the prognos-
tic significance of the WHO classification, especially within
typeB thymomas, is one of the reasons that our study focused
on this specific type of thymomas. In our series, we found no
significant differences in the incidence of recurrence and
survival among the 3 subtypes of type B thymomas.
These findings could be interpreted in several ways. First,
there is substantial interobserver variability in the histologic
typing of thymic epithelial tumors. Shimosato11 reported
that the difference between type B2 and B3 thymomas
appears difficult to distinguish and the definition of the 2
subtypes varies among authors. Rieker and associates10
assessed the interobserver agreement within various histo-
logic subtypes, based on the WHO classification. The inter-
observer agreement was good for all WHO histologic types,
but it was only moderate for type B tumors. Second, the
WHO classification does not clearly specify the definition
of combined thymomas, which contain more than onediovascular Surgery c Volume 139, Number 6 1433
TABLE 3. Frequency of tumor recurrence according to WHO
subtypes and Masaoka stages for completely resected patients
WHO subtype
B1 B2 B3
Overall (%) 1/17 (5.9) 2/35 (5.7) 2/27 (7.4)
Stage I 0/10 0/19 0/9
Stage II 0/5 0/9 0/10
Stage III 1/2 2/5 2/8
Stage IVa — 0/2 —
The number of patients with tumor recurrence was counted among patients undergoing
complete resection.
FIGURE 2. A, Comparison of disease-free survival of patients undergoing
complete resection among WHO subtypes. B, Comparison of disease-free
survival of patients undergoing complete resection among Masaoka stages.
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ates,4 thymomas were classified as type B3 when the B3-
like areas accounted for more than 30% of the total area.
Conversely, in a study by Nakagawa and coworkers,3 thy-
momas were classified as type B3 when there were any areas
of B3 histologic features. However, Stro¨bel and colleagues5
pointed out that combined thymomas share similar clinical
findings with their noncombined counterparts with the
most aggressive component of the tumor. In our series, al-
though a pathologist reviewed all specimens according to
the current WHO classification, the proportion of one sub-
type to another in combined thymomas was not fully quan-
tified on the basis of established guidelines. Tumors that are
predominantly type B1 but contain a small amount of type
B3 tumor may not represent ‘‘pure’’ B1 tumors. However,
it is difficult to know how much this would have affected
the outcome of this study.
The inability of the WHO classification to differentiate
prognosis in our series is also related to the fact that there
was no significant correlation between WHO histologic
types and Masaoka stages in our study population. This is
in contrast to previous reports in which the WHO types
closely correlated with the Masaoka stages.2-7 If we had
dealt with the full spectrum of histologic types and had not
focused on type B thymomas, the correlation might have
been more obvious. However, it should be noted that type
B1 tumors at an advanced stage and type B3 tumors at an
early stage were relatively more frequent in our series than
in previous studies. Although the WHO histologic types re-
flect the biologic nature or aggressiveness of thymomas, the
extent of the disease mainly depends on whether the tumor is
diagnosed at an early or advanced stage. This is why the
WHO classification failed to show prognostic relevance in
our study. Type B3 thymomas, detected at an early stage,
could be completely resected despite the biological aggres-
siveness, and this can be translated into a good prognosis.
In the present study, although there was no difference in
DFS among WHO subtypes, we found that differences in
DFS were significant among Masaoka stages. Therefore,
the Masaoka staging system, which reflects the extent or in-
vasiveness of thymomas, can predict the prognosis better1434 The Journal of Thoracic and Cardiovascular Surthan the WHO classification, and tumor invasiveness or
extent is the most important prognostic factor.7,12-14
Given the chance of recurrence for type B2 or B3 thymo-
mas at an advanced stage, adjuvant therapy should be con-
sidered in such patients. In our study, 5 patients had
a recurrence during follow-up after complete resection,
and among these, all but 1 patient underwent adjuvant radio-
therapy. This suggests that adjuvant radiation therapy was
not effective in these patients. Inasmuch as 4 patients had
pleural dissemination and 4 had pulmonary metastasis, me-
diastinal irradiation alone might not prevent pleura-based re-
currence.15 On the other hand, among the 47 patients who
underwent complete resection for type B2 or B3 thymomas
at Masaoka stage I or II, 37 (79%) received adjuvant radia-
tion therapy, whereas 10 (21%) did not. During follow-up,
none of the patients had a recurrence irrespective of adjuvant
therapy. These results raise questions about the need for ad-
juvant therapy in patients with completely resected stage I or
II thymomas, even for those with type B2 or B3 histologic
characteristics. Adjuvant radiotherapy has been advocatedgery c June 2010
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of the high-risk type B2 or B3 subtype,15-18 whereas 2 recent
studies dealing with this problem found no significant differ-
ences between treated and untreated patients.19,20 More pro-
spective data are required to assess the benefit of adjuvant
radiation therapy in patients with completely resected stage
II type B2 or B3 thymomas.
Because our data were retrospectively collected and ana-
lyzed, our study has intrinsic limitations. Although patients
with advanced stages of thymomas received adjuvant treat-
ment, indications of adjuvant therapy were not consistent,
and this might have affected the outcomes. The study popu-
lation was rather small, limiting the power of our findings.
Furthermore, as described earlier, combined thymomas
were not meticulously dealt with in our study. Despite these
limitations, however, tumor recurrence was significantly as-
sociated with advanced Masaoka stages rather than WHO
types, andMasaoka stage was the most important prognostic
factor in patients with type B thymoma.
In summary, we retrospectively reviewed the recurrence
pattern and long-term survival in patients who underwent
thymectomy for WHO type B thymomas. We compared
the prognosis among subtypes within type B thymomas ac-
cording to both Masaoka staging system and the WHO clas-
sification system. The long-term results demonstrated that
tumor recurrence was significantly associated with advanced
Masaoka stages, irrespective of the WHO classification. No
significant difference was found in DFS among the histo-
logic subtypes, whereas there were significant differences
in DFS among the Masaoka stages. Given the heterogeneity
ofWHO type B thymomas, Masaoka stage should always be
considered when predicting prognosis and planning treat-
ment, including adjuvant treatment for patients with type
B thymomas. Our results should be confirmed by other
prospective studies.References
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TABLE E1. Treatment modalities according to WHO subtypes for all
patients
WHO subtype
B1 (n ¼ 22) B2 (n ¼ 43) B3 (n ¼ 35)
No. % No. % No. %
Complete resection 17 77 35 81 27 77
Treatment
Surgery alone 9 41 6 14 11 31
SurgeryþRT 12 54 33 77 22 63
SurgeryþCT — — 4 9 1 3
SurgeryþCRT 1 5 — — 1 3
RT, Radiation therapy; CT, chemotherapy; CRT, chemoradiation.
TABLE E2. Frequency of tumor recurrence according to WHO
subtypes, Masaoka stages, and radiation therapy for patients
undergoing complete resection
WHO subtype
B1 B2 B3
RT No RT RT No RT RT No RT
Stage I 0/5 0/5 0/16 0/3 0/6 0/3
Stage II 0/4 0/1 0/8 0/1 0/7 0/3
Stage III 1/2 — 2/4 0/1 1/7 1/1
Stage IVa — — — 0/2 — —
Stage I 0/5 0/5 0/16 0/3 0/6 0/3
RT, Radiation therapy.
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